CPRX CATALYST PHARMACEUTICALS, INC.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Pharmaceutical development and commercialization, primarily focused on therapies for rare neuromuscular diseases
• • New emphasis: $200 million share repurchase program initiated October 2025, aimed at returning capital to shareholders

Risk Factors

• • Paragraph IV litigation with Hetero USA on FIRDAPSE® patents expiring 2032–2037, trial scheduled March 23, 2026
• • Exposure to Most Favored Nation pricing proposals under GUARD and GLOBE Medicare projects, impacting realized drug sale prices

Management Discussion & Analysis

• • Revenue $589.0M in 2025, up $97.3M YoY from $491.7M; net product revenue $588.8M vs $489.3M, driven by AGAMREE® launch and FIRDAPSE® volume growth
• • Operating margin implied by net income $214.3M (up from $163.9M) on revenues $589.0M, net income margin ~36.4% vs ~33.3% in 2024

Management Discussion & Analysis

• • No quarterly revenue or YoY financial figures provided in text
• • No profitability or margin data included in MD&A section

Risk Factors

• • New risk: generic competition for FYCOMPA® tablets began entering market, threatening revenue and potential intangible asset impairment
• • Updated legal risk: ongoing litigation enforcement against Paragraph IV challenger seeking generic FIRDAPSE® entry intensified

What are the latest CPRX SEC filings in 2026?

CATALYST PHARMACEUTICALS, INC. (CPRX) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on March 19, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did CPRX file its most recent 10-K annual report?

CATALYST PHARMACEUTICALS, INC. (CPRX) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view CPRX 10-Q quarterly reports?

CATALYST PHARMACEUTICALS, INC. (CPRX)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every CPRX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has CPRX filed recently?

CATALYST PHARMACEUTICALS, INC. (CPRX)'s most recent 8-K was filed on March 19, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find CPRX insider trading activity (Form 4)?

SignalX aggregates every CPRX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does CPRX file with the SEC?

CATALYST PHARMACEUTICALS, INC. (CPRX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new CPRX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for CATALYST PHARMACEUTICALS, INC. (CPRX).

What is CPRX's SEC CIK number?

CATALYST PHARMACEUTICALS, INC. (CPRX)'s SEC CIK (Central Index Key) number is 1369568. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1369568 to look up all CPRX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find CPRX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from CATALYST PHARMACEUTICALS, INC. (CPRX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.